Meeting
2019 ASCO Annual Meeting
Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients.
Authors
Bo Chen
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Department of Breast Cancer, Guangzhou, China
Bo Chen , Ning Liao , Guo-Chun Zhang , Yulei Wang , Xiaoqing Chen , Liping Guo , Li Cao , Hsiaopei Mok , Chong-Yang Ren , Kai Li , Minghan Jia , Cheukfai Li , Ling-Zhu Wen , Jiali Lin , Guangnan Wei , Ting Hou , Analyn Lizaso , Jing Liu , Charles M. Balch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 543)
DOI
10.1200/JCO.2019.37.15_suppl.543
Abstract #
543
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2017 ASCO Annual Meeting
Molecular profiling comparison of breast cancer subtypes in young women and older women.
First Author: Antoinette R. Tan
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes
Poster
2019 ASCO Annual Meeting
Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients.
First Author: Damien Mikael Hansra